APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Urological Medications

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Urological Medications Market Analysis and Forecast 2026-2032

Report ID 17404467022 January 2026192 pages

Choose your research edition.

Industry ResearchUrological Medications Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Urological Medications Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Urological Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urological Medications Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Urological Medications Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Urological Medications market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Urological Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Urological Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Urological Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Urological Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Urological Medications include Abbott, Novartis, Merck, Lilly, Pfizer, GlaxoSmithKline, AbbVie, Viatris and Sanofi-aventis U.S. LLC, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Urological Medications, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Urological Medications, also provides the revenue of main regions and countries. Of the upcoming market potential for Urological Medications, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Urological Medications revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Urological Medications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Urological Medications revenue, projected growth trends, production technology, application and end-user industry.

Urological Medications Segment by Company

Abbott

Novartis

Merck

Lilly

Pfizer

GlaxoSmithKline

AbbVie

Viatris

Sanofi-aventis U.S. LLC

Piramal Pharma Solutions

Mallinckrodt

Endo International

Bayer HealthCare Pharmaceuticals

Astellas Pharma

ADVANZ PHARMA

Urological Medications Segment by Type

Anticholinergics

Alpha Blockers

5-Alpha Inhibitors

Others

Urological Medications Segment by Application

OAB

ED

Prostate Cancer

BPH

SUI

Others

Urological Medications Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urological Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Urological Medications in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Urological Medications company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Urological Medications revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Urological Medications Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Anticholinergics Major Player Table 3. Alpha Blockers Major Player Table 4. 5-Alpha Inhibitors Major Player Table 5. Others Major Player Table 6. Global Urological Medications Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. OAB Major Player Table 8. ED Major Player Table 9. Prostate Cancer Major Player Table 10. BPH Major Player Table 11. SUI Major Player Table 12. Others Major Player Table 13. Urological Medications Industry Trends Table 14. Urological Medications Industry Drivers Table 15. Urological Medications Industry Opportunities and Challenges Table 16. Urological Medications Industry Restraints Table 17. Global Urological Medications Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Urological Medications Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Urological Medications Market Share by Region (2021-2026) Table 20. Global Urological Medications Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Urological Medications Market Share by Region (2027-2032) Table 22. Global Urological Medications Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Urological Medications Revenue Market Share by Players (2021-2026) Table 24. Global Urological Medications Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Urological Medications Key Players Headquarters & Area Served Table 26. Global Urological Medications Players, Product Type & Application Table 27. Global Urological Medications Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Urological Medications by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Urological Medications Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Urological Medications Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Urological Medications Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Urological Medications Revenue Market Share by Type (2021-2026) Table 34. Global Urological Medications Revenue Market Share by Type (2027-2032) Table 35. Global Urological Medications Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Urological Medications Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Urological Medications Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Urological Medications Revenue Market Share by Application (2021-2026) Table 39. Global Urological Medications Revenue Market Share by Application (2027-2032) Table 40. Abbott Company Information Table 41. Abbott Business Overview Table 42. Abbott Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Abbott Urological Medications Product Portfolio Table 44. Abbott Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Urological Medications Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Urological Medications Product Portfolio Table 54. Merck Recent Development Table 55. Lilly Company Information Table 56. Lilly Business Overview Table 57. Lilly Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Lilly Urological Medications Product Portfolio Table 59. Lilly Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Pfizer Urological Medications Product Portfolio Table 64. Pfizer Recent Development Table 65. GlaxoSmithKline Company Information Table 66. GlaxoSmithKline Business Overview Table 67. GlaxoSmithKline Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. GlaxoSmithKline Urological Medications Product Portfolio Table 69. GlaxoSmithKline Recent Development Table 70. AbbVie Company Information Table 71. AbbVie Business Overview Table 72. AbbVie Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. AbbVie Urological Medications Product Portfolio Table 74. AbbVie Recent Development Table 75. Viatris Company Information Table 76. Viatris Business Overview Table 77. Viatris Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Viatris Urological Medications Product Portfolio Table 79. Viatris Recent Development Table 80. Sanofi-aventis U.S. LLC Company Information Table 81. Sanofi-aventis U.S. LLC Business Overview Table 82. Sanofi-aventis U.S. LLC Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Sanofi-aventis U.S. LLC Urological Medications Product Portfolio Table 84. Sanofi-aventis U.S. LLC Recent Development Table 85. Piramal Pharma Solutions Company Information Table 86. Piramal Pharma Solutions Business Overview Table 87. Piramal Pharma Solutions Urological Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Piramal Pharma Solutions Urological Medications Product Portfolio Table 89. Piramal Pharma Solutions Recent Development Table 90. Mallinckrodt Company Information Table 91. Mallinckrodt Business Overview Table 92. Mallinckrodt Urological Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Mallinckrodt Urological Medications Product Portfolio Table 94. Mallinckrodt Recent Development Table 95. Endo International Company Information Table 96. Endo International Business Overview Table 97. Endo International Urological Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Endo International Urological Medications Product Portfolio Table 99. Endo International Recent Development Table 100. Bayer HealthCare Pharmaceuticals Company Information Table 101. Bayer HealthCare Pharmaceuticals Business Overview Table 102. Bayer HealthCare Pharmaceuticals Urological Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio Table 104. Bayer HealthCare Pharmaceuticals Recent Development Table 105. Astellas Pharma Company Information Table 106. Astellas Pharma Business Overview Table 107. Astellas Pharma Urological Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Astellas Pharma Urological Medications Product Portfolio Table 109. Astellas Pharma Recent Development Table 110. ADVANZ PHARMA Company Information Table 111. ADVANZ PHARMA Business Overview Table 112. ADVANZ PHARMA Urological Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. ADVANZ PHARMA Urological Medications Product Portfolio Table 114. ADVANZ PHARMA Recent Development Table 115. North America Urological Medications Revenue by Type (2021-2026) & (US$ Million) Table 116. North America Urological Medications Revenue by Type (2027-2032) & (US$ Million) Table 117. North America Urological Medications Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Urological Medications Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Urological Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Urological Medications Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Urological Medications Revenue by Country (US$ Million) & (2027-2032) Table 122. Europe Urological Medications Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Urological Medications Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Urological Medications Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Urological Medications Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Urological Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Urological Medications Revenue by Country (2021-2026) & (US$ Million) Table 128. Europe Urological Medications Revenue by Country (US$ Million) & (2027-2032) Table 129. China Urological Medications Revenue by Type (2021-2026) & (US$ Million) Table 130. China Urological Medications Revenue by Type (2027-2032) & (US$ Million) Table 131. China Urological Medications Revenue by Application (2021-2026) & (US$ Million) Table 132. China Urological Medications Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Urological Medications Revenue by Type (2021-2026) & (US$ Million) Table 134. Asia Urological Medications Revenue by Type (2027-2032) & (US$ Million) Table 135. Asia Urological Medications Revenue by Application (2021-2026) & (US$ Million) Table 136. Asia Urological Medications Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Urological Medications Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Urological Medications Revenue by Region (US$ Million) & (2021-2026) Table 139. Asia Urological Medications Revenue by Region (US$ Million) & (2027-2032) Table 140. SAMEA Urological Medications Revenue by Type (2021-2026) & (US$ Million) Table 141. SAMEA Urological Medications Revenue by Type (2027-2032) & (US$ Million) Table 142. SAMEA Urological Medications Revenue by Application (2021-2026) & (US$ Million) Table 143. SAMEA Urological Medications Revenue by Application (2027-2032) & (US$ Million) Table 144. SAMEA Urological Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. SAMEA Urological Medications Revenue by Country (2021-2026) & (US$ Million) Table 146. SAMEA Urological Medications Revenue by Country (US$ Million) & (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Urological Medications Image Figure 2. Global Urological Medications Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urological Medications Market Size Share 2021 VS 2025 VS 2032 Figure 4. Anticholinergics Image Figure 5. Alpha Blockers Image Figure 6. 5-Alpha Inhibitors Image Figure 7. Others Image Figure 8. Global Urological Medications Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Urological Medications Market Size Share 2021 VS 2025 VS 2032 Figure 10. OAB Image Figure 11. ED Image Figure 12. Prostate Cancer Image Figure 13. BPH Image Figure 14. SUI Image Figure 15. Others Image Figure 16. Global Urological Medications Market Size (US$ Million) & (2021-2032) Figure 17. Global Urological Medications Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Urological Medications Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Urological Medications Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Urological Medications Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Urological Medications Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Urological Medications Revenue Market Share by Type (2021-2032) Figure 24. Global Urological Medications Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Urological Medications Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Urological Medications Revenue Market Share by Application (2021-2032) Figure 27. North America Urological Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Urological Medications Revenue Share by Type (2021-2032) Figure 29. North America Urological Medications Revenue Share by Application (2021-2032) Figure 30. North America Urological Medications Revenue Share by Country (2021-2032) Figure 31. United States Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Urological Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Urological Medications Revenue Share by Type (2021-2032) Figure 36. Europe Urological Medications Revenue Share by Application (2021-2032) Figure 37. Europe Urological Medications Revenue Share by Country (2021-2032) Figure 38. Germany Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Urological Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Urological Medications Revenue Share by Type (2021-2032) Figure 48. China Urological Medications Revenue Share by Application (2021-2032) Figure 49. Asia Urological Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Urological Medications Revenue Share by Type (2021-2032) Figure 51. Asia Urological Medications Revenue Share by Application (2021-2032) Figure 52. Asia Urological Medications Revenue Share by Region (2021-2032) Figure 53. Japan Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Urological Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Urological Medications Revenue Share by Type (2021-2032) Figure 61. SAMEA Urological Medications Revenue Share by Application (2021-2032) Figure 62. SAMEA Urological Medications Revenue Share by Country (2021-2032) Figure 63. Brazil Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Urological Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergics
  • Alpha Blockers
  • 5-Alpha Inhibitors
  • Others
Applications
  • OAB
  • ED
  • Prostate Cancer
  • BPH
  • SUI
  • Others
Companies covered
  • Abbott
  • Novartis
  • Merck
  • Lilly
  • Pfizer
  • GlaxoSmithKline
  • AbbVie
  • Viatris
  • Sanofi-aventis U.S. LLC
  • Piramal Pharma Solutions
  • Mallinckrodt
  • Endo International
  • Bayer HealthCare Pharmaceuticals
  • Astellas Pharma
  • ADVANZ PHARMA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Urological Medications Market by Type
  3. 1.2.1 Global Urological Medications Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Anticholinergics
  5. 1.2.3 Alpha Blockers
  6. 1.2.4 5-Alpha Inhibitors
  7. 1.2.5 Others
  8. 1.3 Urological Medications Market by Application
  9. 1.3.1 Global Urological Medications Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 OAB
  11. 1.3.3 ED
  12. 1.3.4 Prostate Cancer
  13. 1.3.5 BPH
  14. 1.3.6 SUI
  15. 1.3.7 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Urological Medications Market Dynamics
  1. 2.1 Urological Medications Industry Trends
  2. 2.2 Urological Medications Industry Drivers
  3. 2.3 Urological Medications Industry Opportunities and Challenges
  4. 2.4 Urological Medications Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Urological Medications Market Perspective (2021-2032)
  2. 3.2 Global Urological Medications Growth Trends by Region
  3. 3.2.1 Global Urological Medications Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Urological Medications Market Size by Region (2021-2026)
  5. 3.2.3 Global Urological Medications Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Urological Medications Revenue by Players
  2. 4.1.1 Global Urological Medications Revenue by Players (2021-2026)
  3. 4.1.2 Global Urological Medications Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Urological Medications Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Urological Medications Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Urological Medications Key Players Headquarters & Area Served
  7. 4.4 Global Urological Medications Players, Product Type & Application
  8. 4.5 Global Urological Medications Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Urological Medications Market CR5 and HHI
  11. 4.6.3 2025 Urological Medications Tier 1, Tier 2, and Tier 3
5 Urological Medications Market Size by Type
  1. 5.1 Global Urological Medications Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Urological Medications Revenue by Type (2021-2032)
  3. 5.3 Global Urological Medications Revenue Market Share by Type (2021-2032)
6 Urological Medications Market Size by Application
  1. 6.1 Global Urological Medications Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Urological Medications Revenue by Application (2021-2032)
  3. 6.3 Global Urological Medications Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Urological Medications Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Urological Medications Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Urological Medications Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Urological Medications Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Urological Medications Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Urological Medications Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Lilly
  20. 7.4.1 Lilly Company Information
  21. 7.4.2 Lilly Business Overview
  22. 7.4.3 Lilly Urological Medications Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Lilly Urological Medications Product Portfolio
  24. 7.4.5 Lilly Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Urological Medications Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Urological Medications Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GlaxoSmithKline
  32. 7.6.1 GlaxoSmithKline Company Information
  33. 7.6.2 GlaxoSmithKline Business Overview
  34. 7.6.3 GlaxoSmithKline Urological Medications Revenue and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline Urological Medications Product Portfolio
  36. 7.6.5 GlaxoSmithKline Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Urological Medications Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Urological Medications Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Urological Medications Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Urological Medications Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 Sanofi-aventis U.S. LLC
  50. 7.9.1 Sanofi-aventis U.S. LLC Company Information
  51. 7.9.2 Sanofi-aventis U.S. LLC Business Overview
  52. 7.9.3 Sanofi-aventis U.S. LLC Urological Medications Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sanofi-aventis U.S. LLC Urological Medications Product Portfolio
  54. 7.9.5 Sanofi-aventis U.S. LLC Recent Developments
  55. 7.10 Piramal Pharma Solutions
  56. 7.10.1 Piramal Pharma Solutions Company Information
  57. 7.10.2 Piramal Pharma Solutions Business Overview
  58. 7.10.3 Piramal Pharma Solutions Urological Medications Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Piramal Pharma Solutions Urological Medications Product Portfolio
  60. 7.10.5 Piramal Pharma Solutions Recent Developments
  61. 7.11 Mallinckrodt
  62. 7.11.1 Mallinckrodt Company Information
  63. 7.11.2 Mallinckrodt Business Overview
  64. 7.11.3 Mallinckrodt Urological Medications Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Mallinckrodt Urological Medications Product Portfolio
  66. 7.11.5 Mallinckrodt Recent Developments
  67. 7.12 Endo International
  68. 7.12.1 Endo International Company Information
  69. 7.12.2 Endo International Business Overview
  70. 7.12.3 Endo International Urological Medications Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Endo International Urological Medications Product Portfolio
  72. 7.12.5 Endo International Recent Developments
  73. 7.13 Bayer HealthCare Pharmaceuticals
  74. 7.13.1 Bayer HealthCare Pharmaceuticals Company Information
  75. 7.13.2 Bayer HealthCare Pharmaceuticals Business Overview
  76. 7.13.3 Bayer HealthCare Pharmaceuticals Urological Medications Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bayer HealthCare Pharmaceuticals Urological Medications Product Portfolio
  78. 7.13.5 Bayer HealthCare Pharmaceuticals Recent Developments
  79. 7.14 Astellas Pharma
  80. 7.14.1 Astellas Pharma Company Information
  81. 7.14.2 Astellas Pharma Business Overview
  82. 7.14.3 Astellas Pharma Urological Medications Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Astellas Pharma Urological Medications Product Portfolio
  84. 7.14.5 Astellas Pharma Recent Developments
  85. 7.15 ADVANZ PHARMA
  86. 7.15.1 ADVANZ PHARMA Company Information
  87. 7.15.2 ADVANZ PHARMA Business Overview
  88. 7.15.3 ADVANZ PHARMA Urological Medications Revenue and Gross Margin (2021-2026)
  89. 7.15.4 ADVANZ PHARMA Urological Medications Product Portfolio
  90. 7.15.5 ADVANZ PHARMA Recent Developments
8 North America
  1. 8.1 North America Urological Medications Revenue (2021-2032)
  2. 8.2 North America Urological Medications Revenue by Type (2021-2032)
  3. 8.2.1 North America Urological Medications Revenue by Type (2021-2026)
  4. 8.2.2 North America Urological Medications Revenue by Type (2027-2032)
  5. 8.3 North America Urological Medications Revenue Share by Type (2021-2032)
  6. 8.4 North America Urological Medications Revenue by Application (2021-2032)
  7. 8.4.1 North America Urological Medications Revenue by Application (2021-2026)
  8. 8.4.2 North America Urological Medications Revenue by Application (2027-2032)
  9. 8.5 North America Urological Medications Revenue Share by Application (2021-2032)
  10. 8.6 North America Urological Medications Revenue by Country
  11. 8.6.1 North America Urological Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Urological Medications Revenue by Country (2021-2026)
  13. 8.6.3 North America Urological Medications Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Urological Medications Revenue (2021-2032)
  2. 9.2 Europe Urological Medications Revenue by Type (2021-2032)
  3. 9.2.1 Europe Urological Medications Revenue by Type (2021-2026)
  4. 9.2.2 Europe Urological Medications Revenue by Type (2027-2032)
  5. 9.3 Europe Urological Medications Revenue Share by Type (2021-2032)
  6. 9.4 Europe Urological Medications Revenue by Application (2021-2032)
  7. 9.4.1 Europe Urological Medications Revenue by Application (2021-2026)
  8. 9.4.2 Europe Urological Medications Revenue by Application (2027-2032)
  9. 9.5 Europe Urological Medications Revenue Share by Application (2021-2032)
  10. 9.6 Europe Urological Medications Revenue by Country
  11. 9.6.1 Europe Urological Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Urological Medications Revenue by Country (2021-2026)
  13. 9.6.3 Europe Urological Medications Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Urological Medications Revenue (2021-2032)
  2. 10.2 China Urological Medications Revenue by Type (2021-2032)
  3. 10.2.1 China Urological Medications Revenue by Type (2021-2026)
  4. 10.2.2 China Urological Medications Revenue by Type (2027-2032)
  5. 10.3 China Urological Medications Revenue Share by Type (2021-2032)
  6. 10.4 China Urological Medications Revenue by Application (2021-2032)
  7. 10.4.1 China Urological Medications Revenue by Application (2021-2026)
  8. 10.4.2 China Urological Medications Revenue by Application (2027-2032)
  9. 10.5 China Urological Medications Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Urological Medications Revenue (2021-2032)
  2. 11.2 Asia Urological Medications Revenue by Type (2021-2032)
  3. 11.2.1 Asia Urological Medications Revenue by Type (2021-2026)
  4. 11.2.2 Asia Urological Medications Revenue by Type (2027-2032)
  5. 11.3 Asia Urological Medications Revenue Share by Type (2021-2032)
  6. 11.4 Asia Urological Medications Revenue by Application (2021-2032)
  7. 11.4.1 Asia Urological Medications Revenue by Application (2021-2026)
  8. 11.4.2 Asia Urological Medications Revenue by Application (2027-2032)
  9. 11.5 Asia Urological Medications Revenue Share by Application (2021-2032)
  10. 11.6 Asia Urological Medications Revenue by Country
  11. 11.6.1 Asia Urological Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Urological Medications Revenue by Country (2021-2026)
  13. 11.6.3 Asia Urological Medications Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Urological Medications Revenue (2021-2032)
  2. 12.2 SAMEA Urological Medications Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Urological Medications Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Urological Medications Revenue by Type (2027-2032)
  5. 12.3 SAMEA Urological Medications Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Urological Medications Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Urological Medications Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Urological Medications Revenue by Application (2027-2032)
  9. 12.5 SAMEA Urological Medications Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Urological Medications Revenue by Country
  11. 12.6.1 SAMEA Urological Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Urological Medications Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Urological Medications Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst